#2 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
“What we’re seeing with cannabis normalization is a real public health communication gap: patients come to me asking serious questions about dosing, drug interactions, and therapeutic windows, but they’re getting their information from recreational culture, not clinical evidence, and that’s a problem we need to address directly in our practices.”
💼 While anecdotal reports of cannabis odor in public spaces may seem tangential to clinical care, they underscore a broader challenge for healthcare providers: the normalization and increasing visibility of cannabis use in communities is outpacing clinicians’ preparedness to screen for and counsel patients on its risks and benefits. The lack of standardized clinical guidelines for cannabis use, combined with variable state legalization policies and patients’ often-inaccurate assumptions about safety, creates a knowledge gap that can affect clinical decision-making across multiple domains including pain management, anxiety, substance use disorders, and pregnancy outcomes. Providers should recognize that public incidents reflecting cannabis use prevalence are a reminder to routinely assess cannabis use in patient histories with the same thoroughness applied to alcohol and tobacco, particularly given emerging evidence linking heavy or early use to psychiatric symptoms, impaired driving, and cannabis use disorder. A practical starting point is incorporating a brief validated cannabis screening question into standard intake assessments and
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it:
